MONOPAR THERAPEUTICS INC (MNPR) Stock Price, Quote, News and Overview
NASDAQ:MNPR - Nasdaq - US61023L2079 - Common Stock - Currency: USD
MNPR Quote, Performance and Key Statistics
MONOPAR THERAPEUTICS INC
NASDAQ:MNPR (1/23/2025, 12:44:16 PM)
36
+2.33 (+6.92%)
The current stock price of MNPR is 36 USD. In the past month the price increased by 41.53%. In the past year, price increased by 1751.53%.
MNPR Latest News, Press Releases and Analysis
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology...
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing...
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
MNPR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.82 | 300.52B | ||
| AMGN | AMGEN INC | 14.33 | 148.03B | ||
| GILD | GILEAD SCIENCES INC | 20.92 | 115.52B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 850.88 | 111.76B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.13 | 75.52B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.08B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.85B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.42B | ||
| NTRA | NATERA INC | N/A | 22.60B | ||
| BIIB | BIOGEN INC | 8.73 | 20.78B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.42B |
Related screens
About MNPR
Company Profile
Monopar Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Wilmette, Illinois and currently employs 10 full-time employees. The company went IPO on 2019-12-19. Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The firm is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The firm has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
Company Info
MONOPAR THERAPEUTICS INC
1000 Skokie Blvd Ste 350
Wilmette ILLINOIS 60091 US
CEO: Chandler Robinson
Employees: 10
Company Website: https://www.monopartx.com/
Investor Relations: http://ir.monopartx.com
Phone: 18473880349
MNPR FAQ
What is the price of MNPR?
The current price of MNPR is 36 USD.
What is the symbol for MONOPAR THERAPEUTICS INC?
The exchange symbol of MONOPAR THERAPEUTICS INC is MNPR and it is listed on the Nasdaq exchange.
On which exchange is MNPR listed?
MNPR is listed on the Nasdaq exchange.
Is MNPR a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for MNPR, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of MNPR.
Does MNPR pay dividends?
MNPR does not pay a dividend.
What is the Price/Earnings (PE) ratio of MNPR?
MNPR does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.97).
What is the Short Interest ratio of MNPR?
The outstanding short interest for MNPR is 0.95% of its float.
MNPR Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to MNPR. When comparing the yearly performance of all stocks, MNPR is one of the better performing stocks in the market, outperforming 99.75% of all stocks.
MNPR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MNPR. No worries on liquidiy or solvency for MNPR as it has an excellent financial health rating, but there are worries on the profitability.
MNPR Financial Highlights
Over the last trailing twelve months MNPR reported a non-GAAP Earnings per Share(EPS) of -1.97. The EPS increased by 45.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -106.67% | ||
| ROE | -130.89% | ||
| Debt/Equity | 0 |
MNPR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to MNPR. The Buy consensus is the average rating of analysts ratings from 9 analysts.